Blog
August 9, 2026
“Dry eye” names a clinical syndrome, not one fluid problem. The two best-known mechanisms are excessive evaporation and insufficient aqueous production. Classifying them helps because a person whose tears disappear rapidly for lack of oil needs a different emphasis from someone whose lacrimal glands produce very little fluid.
The distinction is valuable but imperfect. The ocular surface behaves as a network. Evaporation concentrates tears and drives inflammation; inflammation damages epithelium, goblet cells and glands; pain changes blinking; reduced aqueous volume makes the remaining film more vulnerable to evaporation. Most patients seen in chronic practice are not pure textbook examples.
This article explains how clinicians reason between the two patterns without duplicating Netra’s dry-eye condition overview.
Evaporative dry eye occurs when the aqueous portion of tears is lost to the environment faster than the system can maintain a stable coating. The most common driver is obstructive meibomian-gland dysfunction (MGD), although lid exposure, incomplete blinking, contact lenses and environmental airflow can contribute.
Meibomian glands are long sebaceous glands within the upper and lower tarsal plates. Their openings line the posterior lid margin. With a complete blink, the lids spread meibum over the aqueous tears. This lipid-rich surface reduces evaporation and stabilizes the air–tear interface.
In obstructive MGD, terminal ducts can become blocked and secretion can thicken. Pressure builds within the gland, acini may atrophy and visible gland length can decline. Meibum may be cloudy, granular, toothpaste-like or absent with expression rather than clear and easily flowing. Lid-margin telangiectasia, capped openings, irregularity, rosacea or Demodex may coexist.
MGD is not the only evaporative pathway. A person with a normal lipid layer can still lose tears rapidly if the eyes remain widely open, blinks are incomplete or a facial nerve problem prevents closure. Wind, vehicle vents, CPAP leak and low humidity increase the evaporative load.
Aqueous-deficient dry eye occurs when lacrimal secretion is insufficient to maintain the fluid phase. It may be associated with Sjögren disease or arise without recognized Sjögren disease through aging, medication effects, lacrimal injury, nerve disruption, graft-versus-host disease and other conditions.
The main lacrimal glands receive sensory and autonomic signals. Corneal stimulation triggers reflex secretion; parasympathetic and sympathetic pathways regulate gland output. The fluid contains electrolytes, proteins, antimicrobial factors and growth signals, so deficiency is more than reduced volume.
Very low tear volume leaves a shallow meniscus and reduces the reservoir available after each blink. Evaporation then concentrates the remaining tears rapidly. Interpalpebral staining, conjunctival damage, filamentary keratitis and epithelial defects may develop in severe disease.
Sjögren disease deserves special attention because immune-mediated lacrimal and salivary dysfunction may be part of systemic illness. Dry mouth, dental problems, salivary swelling, fatigue, joint or neurologic symptoms can guide referral, but serology may be negative. Aqueous deficiency should not automatically be labeled Sjögren, and Sjögren should not be excluded by one normal test.
TFOS DEWS III emphasizes etiologic drivers rather than treating evaporative and aqueous disease as rigid competing diagnoses. A low-volume film can have a high surface-to-volume vulnerability, while meibomian dysfunction can coexist with lacrimal inflammation.
Several examples show the overlap:
Classification should therefore answer “What is driving disease enough to target?” rather than “Which permanent label belongs in the chart?” Phenotype can change with treatment, season and systemic disease.
Both patterns can cause burning, foreign-body sensation, redness, fluctuating blur, light sensitivity, fatigue and reflex tearing. Late-day worsening is often associated with evaporation, while marked dry mouth or constant severe dryness suggests aqueous deficiency, but neither clue is definitive.
Evaporative disease may be worse during screens, wind or lens wear. Aqueous-deficient disease may require frequent drops throughout the day and night. Yet a low-volume eye can be extremely sensitive to airflow, and an MGD patient can awaken uncomfortable after nocturnal exposure.
Pain intensity also fails as a volume gauge. Sensitized corneal nerves can produce severe symptoms with modest staining. Diabetes or neurotrophic disease can produce limited symptoms despite significant epithelial damage. Testing must consider sensation and surface integrity, not only the patient’s use of the word “dry.”
The lower tear meniscus is the visible strip of fluid between lid and globe. A very low meniscus supports aqueous deficiency. Normal height does not exclude instability because reflex tearing or recent drops can temporarily increase volume. An abnormally high meniscus may indicate drainage dysfunction or reflex tearing.
Fluorescein or noninvasive breakup testing measures how long the film remains uniform after a blink. Rapid breakup supports instability but does not name the cause. Lipid deficiency, low aqueous volume, poor wettability, exposure and contact lenses can all shorten the interval.
Breakup pattern can add clues. Local immediate breakup may suggest a hydrophobic epithelial spot; inferior breakup may correspond to incomplete blinking or exposure. Technique, dye volume and device influence measurement.
The examiner inspects openings and expresses glands with standardized or gentle pressure. The number of yielding glands, secretion quality and required force matter. Infrared meibography shows morphology and dropout. Interferometry estimates lipid-layer features.
Meibography should not be used as a frightening sales image. Gland structure does not perfectly predict symptoms, and apparent change can reflect image quality or interpretation. Still, extensive dropout may limit how much secretion can be restored and supports preservation of remaining function.
The Schirmer test measures paper-strip wetting over several minutes. Testing without anesthetic includes basal and reflex contributions; anesthetized methods attempt to reduce reflex input. Low values, particularly when repeated in context, support aqueous deficiency. Discomfort, room conditions and reflex tearing create variability.
Phenol-red thread and other tests estimate secretion with different tradeoffs. None should be read as a stand-alone pass/fail verdict.
Fluorescein highlights corneal epithelial disruption, while lissamine green highlights stressed conjunctival cells. Distribution can suggest exposure, aqueous deficiency, lid interaction, toxicity or another disease. Severe staining may require urgent protective care regardless of symptom classification.
A phenotype includes medication, contact-lens, surgical, skin, autoimmune, hormonal, neurologic and environmental history. Dry mouth, dental decay, salivary swelling, rash, arthritis, neuropathy or graft-versus-host history may move systemic evaluation forward. Isotretinoin, anticholinergic medicines and chronic topical preservatives provide different clues.
An evaporative emphasis means excessive water loss is the main immediate failure. Obstructive MGD is the common driver; the tear meniscus may be normal or reduced; breakup is usually rapid; and expression may reveal thick, scant or absent meibum. Lid telangiectasia, plugged openings and gland dropout strengthen the pattern. The priorities are to reduce evaporation and improve the function of lids, blinking and remaining glands.
An aqueous-deficient emphasis means insufficient lacrimal secretion is central. The tear meniscus is often low, Schirmer wetting may be reduced and breakup can still be rapid because the small fluid volume concentrates quickly. Lid findings may be mild, but mixed MGD is common. The priorities are to replenish, conserve or stimulate tears, control inflammation, protect epithelium and determine whether systemic disease is present.
These descriptions are reasoning aids. A patient can occupy both patterns, and treatment can change the findings without eliminating underlying susceptibility.
Ocular rosacea often pushes the phenotype toward evaporative disease through lid-margin inflammation and altered meibum. Facial flushing or papules may be subtle, so the eyelids sometimes provide the first clue. Demodex infestation can create cylindrical debris and inflammation, aggravating gland function. Rosacea and Demodex are not interchangeable, and neither should be diagnosed from symptoms alone.
Sjögren disease strongly raises concern for aqueous deficiency, but meibomian dysfunction may coexist. Hematopoietic stem-cell transplant recipients can develop severe graft-versus-host ocular disease involving lacrimal glands, conjunctiva, lids and epithelium. These patients may need systemic coordination, biologic tears, scleral lenses and aggressive surface protection—not merely frequent retail lubricants.
Thyroid-related lid retraction, proptosis and incomplete closure increase exposure, creating an evaporative mechanism even if meibum is normal. Facial nerve palsy compromises blink and closure. Surface treatment may be urgent while the underlying neurologic or orbital disorder is managed. Mechanical exposure belongs outside a simplistic “MGD versus low tears” debate.
Diabetes may reduce corneal sensation and reflex tearing while affecting epithelial healing and meibomian function. A patient can therefore have aqueous, evaporative and neurosensory components with fewer symptoms than expected. Herpetic disease, multiple corneal surgeries and certain neurologic injuries can create a similar mismatch. Objective damage receives priority even when the patient reports limited discomfort.
Anticholinergic medicines can shift the balance toward reduced secretion. Isotretinoin can affect meibomian glands. Chronic preserved eye drops add surface toxicity; refractive surgery changes corneal nerve feedback; cataract surgery temporarily adds incisions, inflammation and topical exposure. An iatrogenic contributor may be modifiable, but its indication must remain protected through prescriber coordination.
A short breakup time is common in both patterns. It can also appear with corneal irregularity, mucin or glycocalyx disturbance, contact lenses and exposure. Similarly, a low Schirmer result can occur because of medication, nerve dysfunction, lacrimal disease or testing variability. High-quality diagnosis avoids turning one test into a subtype label.
Tear osmolarity illustrates the same principle. Hyperosmolarity is part of the dry-eye cycle and can reflect evaporation or reduced volume. A normal sample does not exclude fluctuating disease, and a high result does not name the driver. MMP-9 indicates an inflammatory marker above a threshold but cannot distinguish MGD from Sjögren disease or prove that a particular anti-inflammatory drug will work.
Meibography can show gland loss, yet structure and secretion do not always align. A patient may have substantial dropout with tolerable symptoms because remaining glands and environment compensate. Another may have limited dropout but severe obstruction and poor secretion. Treatment should not be sold solely from an image.
The diagnostic article explains these tools in more detail. The central point here is that phenotype emerges from convergence: history, volume, stability, lids, surface damage, sensation and systemic context.
Redirect airflow, lower screens, encourage complete blinks and use wraparound protection in wind. These steps do not cure gland obstruction but reduce the demand placed on the lipid layer.
Warm compresses aim to heat the inner lid sufficiently and consistently to soften abnormal meibum. A lukewarm cloth that cools in a minute may feel pleasant without reaching therapeutic temperature. Excessive heat can burn skin or worsen rosacea, so technique and device safety matter.
Lid hygiene targets anterior debris or blepharitis. It should not be equated with aggressively squeezing the glands at home. Expression can be painful and, if improperly performed, may traumatize lids without addressing deeper obstruction.
Demodex, rosacea and bacterial or inflammatory blepharitis require diagnosis-specific therapy. Topical or oral antibiotics may be used for antimicrobial or anti-inflammatory purposes in selected cases. Pregnancy, gastrointestinal effects, photosensitivity and resistance belong in the decision.
Thermal pulsation, controlled lid heating and expression, intense pulsed light and other devices target aspects of MGD. Trials report improvements in selected signs and symptoms, but devices, protocols, comparators and durability vary. Cost and expected benefit should be transparent. A procedure cannot recreate absent glands.
Perfluorohexyloctane ophthalmic solution reduces tear evaporation through a water-free semifluorinated alkane mechanism and has randomized-trial evidence in MGD-associated dry eye. It is a prescription option, not a substitute for diagnosing lid disease or protecting a damaged cornea.
Artificial tears, gels and ointments add lubrication. Preservative-free formulations are often favored with frequent use or a compromised surface. Product choice depends on severity, task, vision blur and coexisting lipid deficiency.
Punctal plugs or cautery slow drainage. They can help selected low-volume eyes but may cause epiphora, irritation, extrusion, canalicular complications or retention of inflammatory tears. Surface inflammation and infection should be considered before occlusion.
Moisture-chamber eyewear and scleral lenses conserve a humid or fluid environment. Scleral lenses can protect severe surfaces and improve optics, but they require expertise, sterile handling and ongoing monitoring.
Topical cyclosporine, lifitegrast and other prescription agents target inflammatory pathways or tear production in selected patients. Short courses of topical corticosteroid may be used under monitoring because steroids can raise pressure, promote cataract and worsen infection. Varenicline nasal spray stimulates the trigeminal parasympathetic pathway to increase tear production.
Autologous serum or platelet-derived products provide biologic components for severe epithelial disease, though preparation, concentration and evidence vary. Persistent epithelial defects or neurotrophic keratopathy require specialized protocols beyond ordinary dry-eye treatment.
Suspected Sjögren disease needs coordinated evaluation; ocular drops do not address lung, kidney, nerve or systemic immune involvement. Rheumatologic therapy does not always normalize tear secretion, so local ocular protection continues.
Lubricants fail when evaporation is too rapid, exposure persists or pain is neuropathic. Warm compresses fail when aqueous deficiency dominates, technique is inadequate or gland tissue is extensively lost. Punctal plugs fail when inflammation, lid disease or drainage anatomy is unaddressed. Anti-inflammatory drops fail when adherence, tolerance, time-to-effect or diagnosis is mismatched.
Treatment failure is not a cue to stack every available product. Reassess the phenotype, technique, dose, duration and alternative diagnoses. A therapy can improve a test without achieving the patient’s functional goal, while symptoms can improve despite ongoing epithelial risk.
When several mechanisms are active, sequence matters. Surface infection or an epithelial defect comes before elective device therapy. Marked inflammation may be controlled before placing plugs that retain tears. Significant obstruction and exposure may be addressed while a prescription anti-inflammatory begins its slower effect. Systemic referral can proceed in parallel when Sjögren disease is suspected.
A staged plan might use four horizons:
This sequencing makes it possible to learn. If five expensive treatments begin in one week, improvement cannot be attributed and adverse effects are hard to identify. Severe disease sometimes requires simultaneous therapy, but the reason should be documented.
Dry-eye tests have biological and measurement variability. A one-second increase in breakup time or a few millimeters of Schirmer wetting may not represent a durable clinical change. Meaningful follow-up combines repeatable signs with patient goals such as reading duration, night comfort, rescue-drop frequency or contact-lens tolerance.
Season and environment should be noted. A patient may improve after an office procedure while also entering a humid season or reducing screen time. That does not make the improvement unreal; it simply makes causal certainty limited. Long-term maintenance should be based on what remains helpful when the broader context is considered.
Symptoms and tissue safety must both be tracked. A patient whose burning improves but staining worsens still needs protection. A patient whose staining clears but pain persists may require neurosensory evaluation rather than endless escalation of gland expression.
A 42-year-old contact-lens wearer reports blur and burning after six hours of screen work. Tear meniscus is reasonable, Schirmer testing is not low, breakup is rapid, blinks are incomplete and gland expression yields thick secretion. The plan emphasizes lens schedule, blink and airflow changes, lid-gland treatment and a suitable lubricant. Punctal plugs are not the automatic first step.
A 58-year-old has constant grittiness, dry mouth, dental caries and frequent nighttime drop use. Tear meniscus and Schirmer wetting are very low, while gland expression is moderately reduced but not the main abnormality. The plan protects the cornea, controls inflammation, considers tear conservation or secretory therapy and coordinates systemic evaluation.
A 70-year-old with Parkinson disease and CPAP use awakens dry and worsens during the day. Blinks are infrequent, mask leak reaches one eye, meniscus is low and MGD is present. No single procedure addresses the entire mechanism. Mask refitting, nocturnal protection, medication review, blink support, lubrication and gland care each have a defined role.
A 35-year-old has disabling burning after refractive surgery, with near-normal volume, modest breakup and little staining. The clinician still treats any surface deficit, but also assesses sensation, neuropathic features, migraine and centralized pain. Repeatedly labeling the condition “evaporative” from one short breakup measurement could delay more appropriate care.
Evaporative disease is common in adults, but young patients can develop MGD with rosacea, isotretinoin, contact lenses, heavy device use or chronic blepharitis. A child with ocular discomfort also needs evaluation for allergy, juvenile inflammatory disease, medication exposure, lid anatomy and less common corneal disorders. Adult products and procedures should not be applied automatically to pediatric eyes.
Aqueous deficiency is more common with age, yet it can occur in younger people with Sjögren disease, graft-versus-host disease, congenital lacrimal disorders, nerve injury or systemic medication. Conversely, an older adult may have predominantly evaporative disease with reasonable secretion. Age changes pretest probability; it does not replace examination.
Menopause is often discussed as if it assigns a patient to one subtype. Hormonal effects involve lacrimal and meibomian tissues, inflammation and pain perception, and individual responses to hormone therapy differ. A complete phenotype is more useful than assuming that all postmenopausal symptoms are aqueous-deficient.
Dry-eye care can become expensive and time-consuming. Preservative-free products, devices, prescription drugs, supplements, procedures and specialty lenses each add cost. A mechanism-specific plan should explain what each purchase targets, what evidence supports it, how long the trial lasts and what outcome would justify continuation.
Burden is itself a clinical outcome. A theoretically comprehensive routine that a patient cannot perform will fail. Simplifying bottle schedules, using reminders, prioritizing one lid intervention and coordinating prescriptions can improve adherence more than adding another unproven product. NRT or any integrative program should meet the same standard of transparent purpose, measurable benefit and review.
Consider a postmenopausal screen worker with rosacea, an antihistamine and low tear meniscus. Gland expression shows thick meibum, Schirmer testing is reduced and fluorescein staining is interpalpebral. Calling this only evaporative would ignore secretion; calling it only aqueous-deficient would ignore lid disease and exposure.
A combined plan might address airflow and blinking, use a suitable lubricant, treat MGD and ocular-surface inflammation, review the antihistamine with its prescriber and ask about dry mouth or systemic symptoms. Interventions can be staged so response remains interpretable.
Another patient may have severe burning after LASIK, normal meniscus, modest breakup and little staining. Escalating gland procedures without evaluating corneal sensation and neuropathic pain would be phenotype error.
Netra Restoration Therapy (NRT) can add individualized complementary support after the phenotype and safety needs are established. For a mixed dry-eye patient, this may include systematic review of sleep, stress, diet, hydration, screens, environment and systemic symptoms; licensed acupuncture; and coordinated integrative strategies with measurable comfort or function goals.
Acupuncture studies have reported improvements in symptoms, tear-breakup time and sometimes Schirmer results, including trials comparing acupuncture or electroacupuncture with artificial tears. Systematic reviews remain limited by heterogeneity, variable control procedures and short follow-up. The evidence does not establish that acupuncture reopens obstructed ducts, grows lost glands or reverses autoimmune destruction.
NRT must remain phenotype-aware. A patient with significant MGD still needs eyelid assessment and appropriate gland care. A patient with severe aqueous deficiency needs corneal protection and possible autoimmune evaluation. Nonsterile herbal liquids must never be placed in the eye, and oral herbs or supplements require interaction review.
Learn about Netra Restoration Therapy and dry eye, Netra Eye Institute’s integrative model, the guide to dry-eye diagnostic testing and how to request an appointment.
These questions turn a shopping list into a care plan.
Yes. Obstruction and altered secretion can exist without dramatic redness. Expression and gland imaging may reveal dysfunction not obvious in a mirror.
No. It supports reduced secretion but has multiple causes and substantial variability. Sjögren evaluation integrates ocular, oral, serologic and sometimes biopsy findings.
Either. Surface irritation can trigger reflex tears in both patterns, and drainage problems can add overflow. Visible watering does not classify tear quality.
Not automatically. Technique, severity, rosacea, skin sensitivity and response matter. A clinician can define a sustainable maintenance plan.
Not categorically. A mixed low-volume patient may benefit, but active lid or surface inflammation, drainage anatomy and epiphora risk should be considered.
Symptoms and tests can change with any effective intervention, but underlying structural or autoimmune drivers may persist. NRT is complementary and should not be marketed as proof that a disease mechanism has been cured.
Evaporative and aqueous-deficient dry eye are best understood as interacting mechanisms. The classification matters because it directs attention: lipids, glands, blinking and exposure on one side; secretion, conservation, inflammation and systemic cause on the other. The patient, however, is rarely confined to one side.
Use symptoms to identify burden, examination to identify mechanisms and follow-up to test the plan. Conventional ocular-surface care protects tissue; daily changes reduce avoidable stress; and NRT may provide monitored adjunctive support without replacing the treatment that each phenotype requires.
Reclassification over time is normal and should guide maintenance rather than be interpreted as diagnostic failure.
Medical Disclaimer: This article provides general education and is not medical advice, diagnosis or treatment. Classification and therapy require an eye examination, and dry-eye symptoms can overlap with infection, corneal injury, autoimmune disease and neuropathic pain. Seek urgent care for sudden loss, severe pain, marked light sensitivity, trauma, discharge or a painful red eye with contact-lens use. Do not stop prescribed medicines or place nonsterile products in the eye. Netra Restoration Therapy is adjunctive and must not delay or replace ocular-surface treatment, rheumatology evaluation, corneal protection or emergency care.
